• Services

    Services

    Inoviem provides a full range of services from drug discovery to clinical development by leveraging its platforms and direct access to human pathological specimens. All the platforms and services are label free with no modification of the original molecules.

    Understand the mode of action of your compound

    Identify and validate drug-target engagement

    Lead compound optimization

    Patient stratification and biomarkers discovery

    Indication prioritization

    Identify biomarkers and clinical pharmacology

    SPR services 

    MoA Screening

  • Technology

    Technology

    Inoviem provides breakthrough protein technologies for each phase of the drug development process.
    One of the major advantages of our label-free technologies used under physiological conditions and in human tissue – NPOT® and PIMS® – is that the test compound retains its original structure, as well as the exact same molecular structure that would be used in therapy

    Preclinical

    How to best identify the Mode of Action of your compound

    Read more

    From preclinical to clinical

    Ensure Phase II study and success of your drug candidate in Phase III

    Read more

    Clinical

    Successfully identify the cohort of patients who will respond to your therapy

    Read more

  • Expertise

    Our expertise in translational pharmacology

    Inoviem offers translational target discovery and drug-target Mode of Action (MoA) based on proprietary label-free technologies, developed in a pathological and physiological environment, that uses human tissue.

    Translational pharmacology expertise

    Pre-clinical to clinical phases

    Read more

    Our innovative approach

    Biomarkers, patient and therapeutic window

    Read more

    Advantages of approach

    Save time and money

    Read more

    How we work with clients

    Tailored methodologies and technologies 

    Read more

  • Knowledge centre
  • About us

    About us

    Inoviem Scientific is a Bioanalytical R&D company established in 2011 in Strasburg – France.

    Our mission

    Our mission is clear: to get the right treatment to the right patients within the right therapeutic window.

    Read more

    Our team

    • Management team
    • Scientific board
    • Supervisory board & investors

    Read more

  • Contact us

Can your molecule become a treatment?

At Inoviem Scientific, we share your goal: to fight diseases and address unmet medical needs. We support every stage of drug development—from target validation to clinical trials—using human pathological tissues and our established platforms working directly on patient tissues. Whether you’re developing small molecules or biologics for cancer, autoimmune, metabolic, or other diseases, we provide enabling information to unlock the full potential of your molecule with faster breakthroughs, lower risks, and a competitive edge.

Our established platforms use real human tissue data to reveal how your drug will perform in the organism, helping you validate targets, understand mechanisms of action, and identify predictive biomarkers—saving you time, money, and resources.

Accelerating and securing the drug development process

Traditional drug development models often fail to predict how a treatment will perform in humans. We change that by working directly with human tissues, providing results that reflect the real-world human response. This real patient-centric approach allows us to:

  • Increased relevance: We use patient-derived materials directly reflecting the human response to potential drugs, providing a more accurate picture of efficacy and safety compared to traditional models. This real-world data helps you flag ineffective treatments sooner, saving valuable time and resources.
  • De-risking your pipeline: We understand drug mechanisms through patient-derived materials allows for early identification of potential issues, saving resources and reducing the risk of costly late-stage failures.
  • Improve clinical trial design: By incorporing predictive biomarkers and patient stratification, we help you select the right cohort of responder patients, improving trial success rates and reducing wasted efforts.

What our clients say 

The Inoviem technology has a great potential as a target ID platform. Service itself was fantastic. Impressed with Inoviem's rigor in performing the experiments, analyzing the data and creating the report, and their overall depth of scientific knowledge.
Brahama Gosh
Brahama GoshPrincipal Scientist, Oncology & Discovery Chemistry at Johnson & Johnson
We were very satisfied by the huge amount of information that can be released by an NPOT analysis. We had very valuable interactions and trust.
Marcello Trevisan
Marcello TrevisanHead of Target Discovery at CHIESI Faramaceutici
We are very satisfied with the work performed in collaboration with Inoviem. The NPOT technology is really original and brings valuable information for target validation, completed by SPR.
Arianne Scoumanne
Arianne ScoumanneSenior Scientist Preclinical R&D at ITEOS
Previous
Next

How we close the gap between pre-clinical and clinical success

Our approach is based on the simple idea that current technologies fail to consider the natural environment in which a drug will have its beneficial effect. Due to concerns about the drug-target mode of action, the target is usually removed from its natural environment, resulting in the loss of important information and biasing the drug development process. The consequences of this are commercialized drugs with unexpected undesired effects or a loss of therapeutic efficacy.

Inoviem avoids this shortcoming by developing label-free technologies working directly on human tissue and using human samples as the analysis substrate; technology and physiology are therefore reconciled.

Ongoing investment in developing complementary technologies ensures that we remain at the forefront of innovation and bring the most creative and effective translational solutions to our clients.

News, events & resources

See more resources

Ready to turn your molecule into a treatment?

Contact us now!

Headquarter
Bioparc 2, 850 boulevard Sébastien Brant,
67400 Illkirch-Graffenstaden

CONTACT US


SERVICES
EXPERTISE

Our expertise in translational pharmacology
Advantages of a translational pharmacology approach
How we work with clients

TECHNOLOGY

Preclinical
From preclinical to clinical
Clinical

RESOURCES
ABOUT US

Our mission
Our team

PRIVACY POLICY
Need Help